Dimerization of the Human Papillomavirus E7 Oncoproteinin Vivo  by CLEMENS, KAREN E. et al.
VIROLOGY 214, 289–293 (1995)
SHORT COMMUNICATION
Dimerization of the Human Papillomavirus E7 Oncoprotein in Vivo
KAREN E. CLEMENS,* ROGER BRENT,† JENO¨ GYURIS,†,1 and KARL MU¨NGER‡,2
*Laboratory of Molecular Virology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892; †Department of Molecular
Biology, Massachusetts General Hospital, and Department of Genetics, Harvard Medical School, Boston, Massachusetts 02114;
and ‡Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115
Received August 1, 1995; accepted October 3, 1995
We have used a yeast two-hybrid system to show that human papillomavirus E7 proteins can form oligomeric complexes
in vivo. The carboxyl-terminal cysteine-rich metal-binding domain is critical for this activity although amino-terminal se-
quences also contribute to oligomerization. Our experiments also reveal that E7 possesses an intrinsic transcription activa-
tion activity in yeast, which resides in the amino terminus of the protein. q 1995 Academic Press, Inc.
Papillomaviruses are small DNA viruses which infect proteins including the retinoblastoma tumor suppressor
epithelial cells and cause the formation of generally be- protein pRB, p107, and p130 (8–13). Complex formation
nign hyperplasias or warts. Of the more than 70 different with these cellular proteins is thought to account for
human papillomaviruses (HPVs), approximately 20 are many biological properties of high-risk HPV E7 proteins,
associated with lesions of the anogenital tract. These including cellular transformation and transcriptional acti-
HPVs are classified into two groups: ‘‘low-risk’’ HPVs vation of the E2F-responsive viral and cellular promoters
(such as HPV-6 and HPV-11), associated with genital (reviewed in 14). These biological properties are shared
warts (condyloma acuminata), which are at low risk for between high-risk HPV E7, the Ad E1A protein, and the
carcinogenic progression, and ‘‘high-risk’’ HPVs (such as TAgs of polyomaviruses. As predicted by their functional
HPV-16 and HPV-18), associated with squamous intraep- similarity, the three classes of viral oncoproteins also
ithelial neoplasias, which are at risk for carcinogenic share structural similarity (15). The amino-terminal 38
progression. Consistent with this classification, approxi- amino acids of E7 are similar to two portions of the Ad
mately 80% of all cervical carcinomas contain high-risk E1A and the polyomavirus TAg sequences which include
HPVs (reviewed in 1). a short portion of conserved region (CR) 1 and the entire
The high-risk HPVs encode two oncoproteins, E6 and CR2. The carboxyl termini of the E7 proteins contain two
E7, which are consistently expressed in HPV-positive copies of a Cys-X-X-Cys sequence motif which has been
cervical cancers (reviewed in 2). In tissue culture, expres- implicated in the binding of zinc ions (16–21; Fig. 1).
sion of high-risk HPV E6 and E7 induces immortalization Interestingly, the papillomavirus E6 proteins also contain
of primary human genital epithelial cells, the normal host similar motifs (16). The spacing between the Cys-X-X-
cells of these viruses (3 –5). Like the oncoproteins of Cys motifs is quite large (29 amino acid residues) in
other small DNA tumor viruses—including the adenovi- the conserved regions and does not contain the highly
rus (Ad) E1A and E1B proteins and the large tumor anti- conserved amino acid residues found in typical zinc fin-
gens (TAgs) of polyomaviruses—HPV E6 and E7 exert ger structures.
their oncogenic functions at least in part by interacting Mutations in the metal-binding domain of E7 either
with and functionally inactivating cellular regulatory pro- have no distinguishable biological phenotypes or inter-
teins. The high-risk HPV E6 proteins bind to and inacti- fere with protein stability (22, 23), suggesting that the
vate the p53 tumor suppressor protein by inducing its carboxyl terminus is critical for the structural and func-
rapid degradation through the ubiquitin-mediated prote- tional integrity of the E7 protein (20, 24). Several studies
olysis system (6, 7). The HPV E7 proteins interact with have suggested that specific biochemical and biological
and functionally inactivate a family of structurally related functions are associated with the carboxyl terminus of
E7. This sequence is necessary for the abrogation of
pRB’s nonspecific DNA-binding property (25), for the dis-
1 Present address: Mitotix Inc., Cambridge MA 02142.
ruption of pRB/E2F-1 transcription factor complexes by2 To whom correspondence and reprint requests should be ad-
HPV-16 E7 (26, 27), and may constitute a low-affinity pRB-dressed at Pathology Department, Harvard Medical School, Goldenson
Building, Room 113A, Boston, MA 02115. Fax: (617) 432-0426. binding site (28). A carboxyl-terminal peptide of E7 was
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(18–20). A detailed characterization of this activity was
complicated by the fact that mutations in this region often
led to decreased protein stability (22, 23). When ex-
pressed in yeast as fusions to the LexA moiety, the car-
boxyl-terminal E7 mutants encoded stable proteins and
were expressed at levels comparable to those of the
wild-type LexA–E7 protein (data not shown). We used
these mutants in a two-hybrid system, the interaction
trap (30–32), to analyze oligomerization of E7 in vivo and
to examine the molecular determinants that are neces-
sary for oligomerization.
Several LexA–E7 fusion proteins, which encode either
the wild-type or the mutant forms of HPV-16 E7, were
used as baits. Additional baits were constructed encod-
ing previously identified structural and functional do-
mains of HPV-16 E7. These include amino acids 2–20
(CR1 homology domain), 2–37 (CR1/CR2 homology do-
mains), and 38–98 (carboxyl-terminal zinc-binding do-
main) (Fig. 1). We found that the E7 protein, when fused
to LexA, activates transcription in the absence of an inter-
acting prey (Table 1). This intrinsic transcriptional activa-
FIG. 1. Structure of the HPV-16 E7 ‘‘bait’’ and ‘‘prey’’ fusion proteins. tion property of E7 mapped primarily to the amino-termi-
The 2-mm HIS3 plasmid pLex202 was used for construction of the baits. nal 37 amino acids of E7, while the carboxyl terminus of
In pLex202 the LexA DNA-binding and dimerization domains (LexA E7 (amino acids 38–98) had a much lower activation
amino acid residues 1–202) (39) are expressed from the constitutive
potential. The level of activation was considerably loweralcohol dehydrogenase (ADH) promoter. The LexA hybrid genes
for a bait containing the full-length HPV-6 E7 coding re-(‘‘baits’’) were prepared using PCR amplification according to the manu-
facturer’s conditions (Perkin–Elmer). The amplified products were gen- gion fused to LexA (data not shown). The intrinsic tran-
erated with oligonucleotide primers generating EcoRI and BamHI re- scriptional activity of the LexA HPV-16 E7 protein was
striction sites at the 5* and 3* termini, respectively, to allow cloning sufficient to induce expression of the integrated LexA-
into the pLex202 plasmid at the EcoRI and BamHI restriction sites. The
responsive LEU2 reporter gene to a level that inducedsequences of the PCR-amplified baits were confirmed by dideoxy-
growth of LexA–E7-expressing yeast reporter cells onnucleotide sequence analysis (Sequenase, USB). The prey plasmid,
pJG4-5, is a 2-mm, TRP1 plasmid that directs the synthesis of the SV40 leucine-deficient plates (data not shown), which has ef-
nuclear localization signal, the B42 acidic activation domain, and the fectively precluded the use of these E7 baits for the
influenza virus HA1 epitope tag —totaling 107 amino acids (31). Fusion screening of a cDNA library to identify novel potential
protein expression is directed from the glucose-repressed, galactose-
interaction partners of the HPV E7 oncoprotein. Consis-inducible GAL1 promoter. Amino acids 2–98 of HPV-16 E7 and 371–
tent with the generally high sensitivity of this bait and928 of the retinoblastoma protein pRB were PCR-generated and cloned
into the EcoRI and XhoI sites of pJG4-5. The cloned products were reporter system, this activity was detected only in yeast
analyzed by dideoxynucleotide sequence analysis (Sequenase, USB). and the LexA–HPV-16 E7 fusion protein did not activate
The pRB prey contains a valine to alanine substitution at amino acid transcription of a LexA-responsive reporter plasmid in
520. Since this mutant protein was able to interact strongly with the
mammalian cells (J. L. Brokaw and K. Mu¨nger, unpub-wild-type E7 bait, it was used in all of the assays presented here.
lished results). Although the possible biological rele-The 2-mm, URA3 reporter plasmid, pJK103 (40), is a medium-sensitivity
LexAop-GAL1-lacZ reporter; it contains a single high-affinity colE1-de- vance of the intrinsic transcriptional activation potential
rived LexA operator and presumably binds four monomers of the LexA of E7, therefore, is presently unknown, it is possible that,
fusion bait (41). The Saccharomyces cerevisiae strain EGY188 (MATa when tethered to DNA, the cryptic activation domain may
trp1 ura3 his3 LEU: :pLexop2-LEU2) was used as a host to analyze
also function in mammalian cells. Interestingly, it hasbait/prey interactions (32). Both the yeast LEU2 gene and the lacZ
been shown that HPV-16 E7 can interact with p107/E2Fgene on pJK103 are transcriptionally silent unless activated by a LexA-
containing protein or protein complex. Yeast transformations were per- transcription factor complexes (33). Although E7 binding
formed according to standard methods (42). does not lead to a physical disruption of this complex
(27, 34, 35), it can result in the activation of specific E2F-
responsive promoters (36). It is therefore an intriguingable to transactivate the Ad E2 promoter when microin-
possibility that, under certain conditions, the transcrip-jected into HeLa cells (29). One study also suggests that
tional activation function of E7 may indeed contribute tothe carboxyl terminus of E7 contains important determi-
its biological activity.nants for the immortalization of primary human genital
To evaluate the overall structural integrity and to char-keratinocytes in cooperation with E6 (24). Spectroscopic
acterize the carboxyl-terminal mutant E7 baits further, weanalyses and biochemical studies have indicated that
also generated a prey where a fragment of pRB (aminothe carboxyl-terminal, cysteine-rich, zinc-binding domain
may be involved in mediating dimer/multimer formation acid residues 371–928) was fused to the B42 activator
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TABLE 1
E7 Oligomerization in Vivoa
No interacting prey pRB prey Full-length E7 prey
Bait (b-galactosidase unitsb) (% b-galactosidase activityc) (% b-galactosidase activityc)
16 E7 2–98 14 100 100
16 E7 2–20 2 3 { 3 0
16 E7 2–37 50 88 { 11 11 { 10
16 E7 38–98 2 0 59 { 16
16 E7 DDLYC 7 25 { 11 67 { 22
16 E7 DEDE 13 125 { 65 88 { 9
16 E7 SS58/59 5 30 { 3 0
16 E7 R67 26 92 { 19 0
16 E7 G77 12 64 98 { 61
16 E7 S91 19 75 { 25 0
a The yeast strain EGY188 was initially transformed with the URA3/ reporter, pJK103, selected on uracil-deficient glucose plates followed by
transformation with bait and prey plasmids (43). One milliliter of overnight culture grown in selective glucose media was washed once in H2O and
resuspended in 10 ml of selective media with galactose to induce prey protein synthesis. At 12 hr postinduction, liquid b-galactosidase assays
were conducted according to standard procedures (44).
b The b-galactosidase activity was calculated with the following formula:
1000 1 OD420 nm
OD600 nm 1 vol (ml) 1 time (min) .
c The values were corrected by subtracting the intrinsic transactivation activity of each individual bait in the absence of an interacting prey. The
values are given in % of transactivation by wild-type E7, which was arbitrarily set to 100%, and represent averages of three experiments.
sequence. In agreement with a previous study (37), HPV- teins had no major defects in protein folding, they were
used to analyze the dimerization domain of E7 in more16 E7 was able to efficiently interact with the pRB prey
in this system and as established by our previous bio- detail. The HPV-16 E7 baits and the HPV-16 E7 prey
shown in Fig. 1 were coexpressed, and protein/proteinchemical experiments, pRB binding was mediated by se-
quences in CR2 (23). The full-length HPV-16 E7 and the interactions were analyzed using the LexAop-lacZ re-
porter and by coimmunoprecipitation (Table 1 and Fig.CR1/CR2 bait (16 E7 2– 37) but not the HPV-16 E7 CR1
bait (16 E7 2–20) efficiently interacted with the pRB prey. 2). Expression of the E7 prey was slightly toxic in yeast,
in that the cell growth rate was slightly reduced uponSimilarly, the deletion of amino acid residues 21 to 24
(16 E7 DDLYC) but not 35 to 37 (16 E7 DEDE) in the induction of prey expression with galactose. This effect
was independent of bait protein coexpression (data notcontext of the full-length E7 protein resulted in a marked
decrease in interaction with pRB. The four mutants in the shown). As shown in Table 1 and Fig. 2, the full-length
HPV-16 E7 bait protein can efficiently interact with thecarboxyl terminus of E7 were all able to interact with the
pRB prey, although at somewhat reduced levels. Most HPV-16 E7 prey. We found that the carboxyl terminus of
E7 (amino acids 38–98) was also able to efficiently inter-strikingly, the reduced pRB-binding efficiency as a conse-
quence of the mutation of the two cysteine residues in act with the full-length E7 prey (transcription at 59% of
wild-type E7; Table 1). The 16 E7 2–37 bait also inter-the 16 E7 SS58/59 bait protein may indicate that the
structural integrity of the E7 protein may be critically de- acted at a very low efficiency with full-length LexA E7
(transcription at 11% of wild-type E7; Table 1), suggestingpendent on the metal-binding sites in the carboxyl termi-
nus (Table 1). Interestingly, deletion of the core pRB- that the carboxyl terminus may not be the sole determi-
nant for oligomerization. In agreement with this idea, thebinding site in CR2 did not completely abrogate pRB prey
binding, possibly supporting some role of the carboxyl two amino-terminal mutants 16 E7 DDLYC and 16 E7
DEDE interacted with the E7 prey at somewhat reducedterminus in pRB binding (28). Although it has been re-
ported that the carboxyl terminus of HPV E7 contains an levels (transcription at 67 and 88%, respectively; Table
1). However, the concept that the carboxyl terminus isindependent, low-affinity pRB-binding site (28), the HPV-
16 E7 carboxyl terminus bait (16 E7 38–98) did not inter- the major determinant for dimerization is clearly sup-
ported by the observation that three of the four testedact with the pRB prey in our experiments. Similar results
were obtained by b-galactosidase (Table 1) and coimmu- LexA E7 preys with mutations in the carboxyl terminus
(16 E7 SS58/59, 16 E7 R67, and 16E7 S91 of E7) hadnoprecipitation analyses (Fig. 2). These results clearly
illustrate the high sensitivity and selectivity of this version lost their ability to bind to the E7 prey (no activation of
transcription above background level; Table 1). Similarof the two-hybrid system.
Since the results with the pRB interaction indicated results were obtained by coimmunoprecipitation analy-
ses (Fig. 2). Not every mutation in the carboxyl terminusthat the carboxyl-terminal mutant LexA–E7 fusion pro-
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FIG. 2. Representative coimmunoprecipitation assays of the LexA–E7 fusion proteins with the E7 prey (top) and the pRB prey (bottom). A 10-ml
culture of cells expressing the corresponding hybrid proteins was grown overnight in selective glucose media, washed in water, and grown in
selective galactose media for 12 hr. Cells were lysed in breaking buffer (0.1 M NaCl, 50 mM Tris, 0.5% NP-40, 0.1 mg/ml phenymethylsulfonylfluoride,
2 mg/ml aprotinin, 2 mg/ml leupeptin, and 0.7 mg/ml pepstatin, pH 8.0) by vortexing in an equal volume of glass beads (Sigma; 425–600 mm). After
centrifugation, the protein concentration of the supernatant was determined by the Bio-Rad assay. An aliquot containing 400 mg of total protein was
immunoprecipitated using 5 mg of 12CA5 antibody (BAbCo) directed against the HA epitope in the prey fusion protein. Immunoprecipitated proteins
were separated on a sodium dodecyl sulfate–10% polyacrylamide gel and electroblotted to Immobilon P membranes (Millipore). Coimmunoprecipita-
tion of LexA–E7 bait proteins was accomplished using a 1:2000 dilution of a rabbit polyclonal antibody to the LexA portion of the bait (a kind gift
of Russ Finley). After incubation with a horseradish peroxidase-linked secondary antibody (Amersham), the baits were detected by enhanced
chemiluminescence (ECL kit, Amersham). Although bait and prey plasmids were expressed at approximately equal levels in all of these experiments
(not shown), no further efforts were made to allow a quantitative interpretation of the data shown in this figure.
interfered with the dimerization/multimerization property not express a stable protein in mammalian cells (23).
Although alternative explanations are possible, these re-of E7, and 16 E7 G77 strongly interacted with E7 by both
b-galactosidase (transcription at 98% of wild-type E7; Ta- sults are consistent with a model where oligomerization
may serve as an indicator for the structural and functionalble 1) and coimmunoprecipitation (Fig. 2) assays. Taken
together, these results suggest that the HPV-16 E7 pro- integrity of the papillomavirus E7 proteins.
The carboxyl termini of the low- and high-risk E7 pro-tein can form oligomeric complexes in vivo. The cysteine-
rich carboxyl terminus of E7 is the major determinant but teins are highly conserved and found to be functionally
interchangeable (38). Thus, it was not surprising that athe amino-terminal CR1/CR2 homology domain of E7 may
also contribute to oligomerization. HPV-6 full-length E7 bait interacted with the HPV-16 E7
prey (data not shown). As with the high-risk HPV E7 pro-As summarized earlier, the carboxyl terminus of E7
exhibits a number of interesting biochemical properties tein, the interaction is dependent on carboxyl-terminal
sequences since a HPV-6 amino-terminal E7 bait (aminoand biological activities. Since alterations in the carboxyl
terminus often compromise protein stability, it has not acids 2–36) did not interact with the full-length HPV-16
E7 prey (data not shown).been possible to establish clearly the importance of
oligomer formation for the functional integrity of E7. It is The carboxyl-terminal Cys-X-X-Cys motifs and the 29-
amino-acid spacing, which appear too large to form aintriguing to note, however, that the one carboxyl-termi-
nal E7 mutant that maintained the ability to form oligo- typical zinc finger structure (20), are conserved in all E7
proteins so far examined and are also present in twomeric complexes in this study (16 E7 G77) also retained
transforming and transcriptional activities in a previous copies in the papillomavirus E6 proteins (16). Therefore,
the E6 protein may also form dimeric/multimeric com-mutagenic analysis conducted in mammalian cells (23).
In contrast, the dimerization-negative mutants 16 E7 plexes. Furthermore, the structurally similar Cys-X-X-Cys
domains of E6 and E7 may allow the formation of hetero-SS58/59 and 16 E7 R67 were impaired in their biological
activities although they were expressed at similar levels. meric complexes which might possess interesting bio-
logical activities. Although, due to the low intracellularThe third dimerization-negative mutant, 16 E7 S91, did
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